Skip to content
OpenCapital
Get started

Palvella Therapeutics PVLA Q4 2025 Annual earnings

Reported March 31, 2026 · Before market open

EPS-$1.08Miss by $0.17
EPS estimate-$0.91

Next report

Aug 13, 2026 (In 2 weeks)
EPS estimate-$1.16

Financials

Q4 2025

Income statement

See full
Operating income-$11.3M-159%
Net income-$12.7M-222%
EPS (diluted)-$1.08—

Balance sheet

See full
Cash & equivalents$58.0M-30.6%
Total debt$633.0K—
Total equity$28.0M-55.3%
Total assets$59.6M-32.5%

Cash flow

See full
Operating cash flow-$4.9M+8.7%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.24B+820%
Enterprise value$1.18B—

Returns & leverage

See full
Return on equity-92.1%—
Debt / equity0×—
Current ratio5.2×-2.1×

Versus estimates

Diluted EPS

Q1 2026-$1.20Miss by $0.30
Q4 2025-$1.08Miss by $0.17
Q3 2025-$1.03Miss by $0.18Q2 2025-$0.86Miss by $0.08Q1 2025-$0.74Beat by $2.66Q4 2024$4.00Beat by $4.39

Ask the moment Palvella Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Palvella Therapeutics report Q4 2025 earnings?
Palvella Therapeutics (PVLA) reported Q4 2025 earnings on March 31, 2026 before market open.
What were Palvella Therapeutics's Q4 2025 revenue and EPS?
Palvella Therapeutics reported eps of $-1.08 for Q4 2025.
Did Palvella Therapeutics beat estimates in Q4 2025?
EPS missed the consensus estimate of $-0.91 by $0.17.
Where can I find Palvella Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-133332) and the 10-K periodic report (0001193125-26-133372) directly on SEC EDGAR. The filing index links above go to sec.gov.